<DOC>
	<DOCNO>NCT00632866</DOCNO>
	<brief_summary>Primary Sjögren 's syndrome ( SJp ) affect 0.1 % population . This systemic autoimmune disease systemic characterize disable dryness , fatigue pain , systemic complication 30 % patient . No treatment proven effective disease . In open study , efficacy observe hydroxychloroquine RCT versus placebo ever do . Thus , primary purpose study evaluate efficacy safety hydroxychloroquine ( 400mg/ day ) dryness , pain , fatigue , assess patient use visual analogical scale .</brief_summary>
	<brief_title>Hydroxychloroquine Versus Placebo Primary Sjögren 's Syndrome</brief_title>
	<detailed_description>Primary Sjögren 's syndrome ( SJp ) affect 0.1 % population . This systemic autoimmune disease systemic characterize disable dryness , fatigue pain , systemic complication 30 % patient . No treatment proven effective disease . In open study , efficacy observe hydroxychloroquine RCT versus placebo ever do . Thus , primary purpose study evaluate efficacy safety hydroxychloroquine ( 400mg/ day ) dryness , pain , fatigue , assess patient use visual analogical scale ( VAS ) . Response define improvement 30 % least 2 3 follow VAS : disabling dryness , fatigue , pain .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Inclusion criterion : Patients suffer primary Sjögren 's syndrome accord EuropeanAmerican consensus group criterion Male female age 18 Conducting clinical examination beforehand . Having undergone less 6 month ophthalmological examination , counterindicated hydroxychloroquine . Patient without heart conduction disturbance ( PR &gt; =0.2 sec QRS &gt; =0.08 sec ) . Patient ability give inform , date sign consent begin proceeding related trial Patients treat corticosteroid / NSAIDs , / cyclosporine , / pilocarpine must receive stable dos treatment month precede inclusion . Exclusion criterion : SJ associate autoimmune disease Retinopathy /severe cataract/ monophthalmos Previous ongoing treatment hydroxychloroquine Treatment another immunosuppressant interrupt least 4 week prior inclusion , 6 month prior inclusion cyclophosphamide rituximab lymphoma severe SJp complication : vasculitis responsible documented renal , neurological , digestive heart involvement , glomerular disease associate hematuria / proteinuria &gt; 0.5 g / ) , CNS involvement , peripheral neurological involvement motor deficiency score 3 less scale 5 , interstitial pneumonitis , recent symptomatic cryoglobulinemia neurological , renal , systemic involvement , myositis motor deficiency ( isolated purpura exclusion criterion ) Chronic Alcoholism Hepatocellular insufficiency Creatinine clearance &lt; 60 ml / min Risk lose followup People young 18 , major trusteeship guardianship , deprive liberty Pregnancy /Breastfeeding Hypersensitivity chloroquine hydroxychloroquine constituent Plaquenil Psoriasis intermittent porphyria . G6PD deficiency , congenital galactosemia , malabsorption syndrome , glucose galactose , lactase deficiency . Nonmembership social security system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>auto-immune disease</keyword>
	<keyword>hydroxychloroquine</keyword>
	<keyword>primary Sjögren 's syndrome</keyword>
	<keyword>inflammatory arthritides</keyword>
	<keyword>inflammatory rheumatic disease</keyword>
	<keyword>dryness</keyword>
	<keyword>joint disease</keyword>
</DOC>